Kurt Von Emster Sells 144,216 Shares of CymaBay Therapeutics Inc (CBAY) Stock

CymaBay Therapeutics Inc (NASDAQ:CBAY) Director Kurt Von Emster sold 144,216 shares of the stock in a transaction on Friday, January 19th. The stock was sold at an average price of $10.25, for a total transaction of $1,478,214.00. Following the sale, the director now owns 90,000 shares of the company’s stock, valued at $922,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kurt Von Emster also recently made the following trade(s):

  • On Friday, January 5th, Kurt Von Emster sold 4,300 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $10.21, for a total transaction of $43,903.00.
  • On Friday, December 22nd, Kurt Von Emster sold 173,192 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $9.41, for a total transaction of $1,629,736.72.
  • On Friday, November 10th, Kurt Von Emster sold 50,048 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $9.26, for a total transaction of $463,444.48.
  • On Tuesday, October 31st, Kurt Von Emster sold 59,209 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $9.27, for a total transaction of $548,867.43.

Shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) traded up $0.25 during midday trading on Monday, reaching $10.45. 667,015 shares of the company traded hands, compared to its average volume of 564,037. The company has a market capitalization of $458.38, a price-to-earnings ratio of -10.35 and a beta of 1.82. CymaBay Therapeutics Inc has a fifty-two week low of $1.46 and a fifty-two week high of $10.60. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). During the same period last year, the company earned ($0.25) EPS. equities analysts anticipate that CymaBay Therapeutics Inc will post -0.82 EPS for the current year.

CBAY has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Piper Jaffray Companies reiterated a “buy” rating and set a $12.00 price objective on shares of CymaBay Therapeutics in a research report on Friday, October 27th. Cantor Fitzgerald reiterated a “buy” rating and set a $16.00 price objective on shares of CymaBay Therapeutics in a research report on Wednesday, November 8th. Oppenheimer set a $15.00 price objective on shares of CymaBay Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 30th. Finally, Leerink Swann reiterated a “buy” rating and set a $16.00 price objective on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $14.50.

A number of hedge funds and other institutional investors have recently modified their holdings of CBAY. Bank of New York Mellon Corp boosted its stake in CymaBay Therapeutics by 0.8% during the second quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 140 shares in the last quarter. Schwab Charles Investment Management Inc. bought a new position in CymaBay Therapeutics during the fourth quarter worth $115,000. Ardsley Advisory Partners boosted its stake in CymaBay Therapeutics by 66.2% during the second quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after acquiring an additional 20,000 shares in the last quarter. Boothbay Fund Management LLC bought a new position in CymaBay Therapeutics during the third quarter worth $404,000. Finally, Crestline Management LP bought a new position in CymaBay Therapeutics during the third quarter worth $841,000. 69.12% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/22/kurt-von-emster-sells-144216-shares-of-cymabay-therapeutics-inc-cbay-stock.html.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Insider Buying and Selling by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply